Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Furst

Showing results (81-90 of 755) with videos related to

Pageof 76
Sort By:
Arthritis and Rheumatism|June 1, 1993
Differential effects of diclofenac and aspirin on serum glutamic oxaloacetic transaminase elevations in patients with rheumatoid arthritis and osteoarthritisD E Furst, W Anderson
Drugs & Aging|December 1, 1995
Disease-modifying antirheumatic drugs. Potential effects in older patientsG Gardner, D E Furst
Expert Opinion on Drug Safety|June 5, 2020
Safety of repository corticotropin injection as an adjunctive therapy for the treatment of rheumatoid arthritisRoy Fleischmann, Daniel E Furst
Current Opinion in Rheumatology|April 1, 1990
Recent clinical pharmacology and clinical trial reportsM A Catalano, D E Furst
Arthritis Research & Therapy|June 6, 2019
Targeting inflammatory pathways in axial spondyloarthritisDaniel E Furst, James S Louie
Annals of the Rheumatic Diseases|September 23, 2010
Rheumatoid arthritis and herpes zoster: risk and prevention in those treated with anti-tumour necrosis factor therapyK L Winthrop, D E Furst
Expert Opinion on Pharmacotherapy|March 16, 2001
RofecoxibJ L Hillson, D E Furst
Arthritis and Rheumatism|April 1, 1992
Decreased hemoglobin levels in nonsteroidal antiinflammatory drug-treated patients may not be related to the drugD I Cargill, D E Furst
The Journal of Rheumatology. Supplement|May 1, 1997
Hypothesis for the pathogenesis of systemic sclerosisD E Furst, P J Clements
Clinics in Geriatric Medicine|May 25, 2005
Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patientVeena K Ranganath, Daniel E Furst
Pageof 76

Showing results (81-90 of 755) with videos related to

Sort By:
Pageof 76
Arthritis and Rheumatism|June 1, 1993
Differential effects of diclofenac and aspirin on serum glutamic oxaloacetic transaminase elevations in patients with rheumatoid arthritis and osteoarthritisD E Furst, W Anderson
Drugs & Aging|December 1, 1995
Disease-modifying antirheumatic drugs. Potential effects in older patientsG Gardner, D E Furst
Expert Opinion on Drug Safety|June 5, 2020
Safety of repository corticotropin injection as an adjunctive therapy for the treatment of rheumatoid arthritisRoy Fleischmann, Daniel E Furst
Current Opinion in Rheumatology|April 1, 1990
Recent clinical pharmacology and clinical trial reportsM A Catalano, D E Furst
Arthritis Research & Therapy|June 6, 2019
Targeting inflammatory pathways in axial spondyloarthritisDaniel E Furst, James S Louie
Annals of the Rheumatic Diseases|September 23, 2010
Rheumatoid arthritis and herpes zoster: risk and prevention in those treated with anti-tumour necrosis factor therapyK L Winthrop, D E Furst
Expert Opinion on Pharmacotherapy|March 16, 2001
RofecoxibJ L Hillson, D E Furst
Arthritis and Rheumatism|April 1, 1992
Decreased hemoglobin levels in nonsteroidal antiinflammatory drug-treated patients may not be related to the drugD I Cargill, D E Furst
The Journal of Rheumatology. Supplement|May 1, 1997
Hypothesis for the pathogenesis of systemic sclerosisD E Furst, P J Clements
Clinics in Geriatric Medicine|May 25, 2005
Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patientVeena K Ranganath, Daniel E Furst
Pageof 76